Search hospitals > New Jersey > Berlin

Hassman Research Institute

Claim this profile
Berlin, New Jersey 08009
Global Leader in Schizophrenia
Global Leader in Depression
Conducts research for Major Depressive Disorder
Conducts research for Opioid Use Disorder
Conducts research for Migraine
140 reported clinical trials
6 medical researchers
Photo of Hassman Research Institute in BerlinPhoto of Hassman Research Institute in BerlinPhoto of Hassman Research Institute in Berlin

Summary

Hassman Research Institute is a medical facility located in Berlin, New Jersey. This center is recognized for care of Schizophrenia, Depression, Major Depressive Disorder, Opioid Use Disorder, Migraine and other specialties. Hassman Research Institute is involved with conducting 140 clinical trials across 112 conditions. There are 6 research doctors associated with this hospital, such as Michael Hassman, DO, Elan Cohen, PhD, Steven Glass, MD, and Steve Glass, MD.

Area of expertise

1Schizophrenia
Global Leader
Hassman Research Institute has run 30 trials for Schizophrenia.
2Depression
Global Leader
Hassman Research Institute has run 24 trials for Depression. Some of their research focus areas include:
Selective Serotonin Reuptake Inhibitors (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)

Top PIs

Clinical Trials running at Hassman Research Institute

Obesity
Schizophrenia
Non-alcoholic Fatty Liver Disease
Attention Deficit Hyperactivity Disorder (ADHD)
Diabetes
Autism
Peanut Allergy
Type 2 Diabetes
Major Depressive Disorder
Obsessive-Compulsive Disorder
Image of trial facility.

Tirzepatide

for Obesity

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Recruiting1 award Phase 39 criteria
Image of trial facility.

PF-07081532 + Rybelsus

for Type 2 Diabetes and PF-07081532

The purpose of this study is to find out if PF-07081532 ("the active study drug"), is safe and helps treat people with obesity without diabetes to lose weight, and people with diabetes to keep their blood sugar in good control. Individuals diagnosed with diabetes that are on metformin or individuals with obesity without diabetes will be included in the study. Those participating in the diabetes part of the study, will receive either active study drug, placebo, or an approved treatment called Rybelsus. Those in the obesity part of the study, will receive either active study drug or placebo. The study will last for about 36 weeks except for the first 25% of the participants that enter in which case the study will last for approximately 48 weeks. during this time there will be visits every 4 weeks with phone calls in between.
Recruiting0 awards Phase 24 criteria
Image of trial facility.

Tirzepatide + Mibavademab

for Obesity

The main purpose of this study is to determine if combining tirzepatide with the mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 72 weeks and may include up to 19 visits.
Recruiting0 awards Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Hassman Research Institute?
Hassman Research Institute is a medical facility located in Berlin, New Jersey. This center is recognized for care of Schizophrenia, Depression, Major Depressive Disorder, Opioid Use Disorder, Migraine and other specialties. Hassman Research Institute is involved with conducting 140 clinical trials across 112 conditions. There are 6 research doctors associated with this hospital, such as Michael Hassman, DO, Elan Cohen, PhD, Steven Glass, MD, and Steve Glass, MD.